Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention.

Nordstrom BL, Simeone JC, Zhao Z, Molife C, McCollam PL, Ye X, Effron MB.

Am J Cardiovasc Drugs. 2013 Aug;13(4):263-71. doi: 10.1007/s40256-013-0028-1.

PMID:
23696167
3.

Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.

Roe MT, Goodman SG, Ohman EM, Stevens SR, Hochman JS, Gottlieb S, Martinez F, Dalby AJ, Boden WE, White HD, Prabhakaran D, Winters KJ, Aylward PE, Bassand JP, McGuire DK, Ardissino D, Fox KA, Armstrong PW.

Circulation. 2013 Aug 20;128(8):823-33. doi: 10.1161/CIRCULATIONAHA.113.002303. Epub 2013 Jul 12.

5.
6.

Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.

Davies A, Bakhai A, Schmitt C, Barrett A, Graham-Clarke P, Sculpher M.

J Med Econ. 2013;16(4):510-21. doi: 10.3111/13696998.2013.768998. Epub 2013 Feb 12.

PMID:
23339464
7.

A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Dasbiswas A, Rao MS, Babu PR, Vijayvergiya R, Nayak R, Dani S, Tyagi S, Hiremath S, Patel T, Alexander T, Prakash VS, Singh DP, Yadav MK, Pathak K, Srivastava A.

J Assoc Physicians India. 2013 Feb;61(2):114-6, 126.

PMID:
24471250
8.

Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators..

N Engl J Med. 2007 Nov 15;357(20):2001-15. Epub 2007 Nov 4.

9.

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.

Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.

J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. doi: 10.1016/j.jacc.2012.03.050.

10.

Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.

Salisbury AC, Wang K, Cohen DJ, Li Y, Jones PG, Spertus JA.

Circ Cardiovasc Qual Outcomes. 2013 Jan 1;6(1):27-34. doi: 10.1161/CIRCOUTCOMES.112.965624. Epub 2012 Dec 4.

11.

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.

Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators..

Eur Heart J. 2008 Oct;29(20):2473-9. doi: 10.1093/eurheartj/ehn362. Epub 2008 Aug 5.

12.

Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.

Parodi G, Bellandi B, Venditti F, Carrabba N, Valenti R, Migliorini A, Grassellini S, Ramazzotti E, Antoniucci D.

Am J Cardiol. 2012 Jan 15;109(2):214-8. doi: 10.1016/j.amjcard.2011.08.034. Epub 2011 Oct 12.

PMID:
21996146
13.

Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome.

Schnapf AJ.

J Cardiovasc Nurs. 2013 Sep-Oct;28(5):483-94. doi: 10.1097/JCN.0b013e31826173ba.

PMID:
22990232
14.

Contemporary use of prasugrel in clinical practice: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.

Sandhu A, Seth M, Dixon S, Share D, Wohns D, Lalonde T, Moscucci M, Riba AL, Grossman M, Gurm HS.

Circ Cardiovasc Qual Outcomes. 2013 May 1;6(3):293-8. doi: 10.1161/CIRCOUTCOMES.111.000060. Epub 2013 May 14.

15.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Kom├│csi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
16.

Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.

Bonello L, Mancini J, Pansieri M, Maillard L, Rossi P, Collet F, Jouve B, Wittenberg O, Laine M, Michelet P, Bessereau J, Lemesle G, Dignat-George F, Paganelli F, Camoin-Jau L.

J Thromb Haemost. 2012 Oct;10(10):1999-2005. doi: 10.1111/j.1538-7836.2012.04875.x.

17.

Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.

Wiviott SD, Desai N, Murphy SA, Musumeci G, Ragosta M, Antman EM, Braunwald E.

Am J Cardiol. 2011 Oct 1;108(7):905-11. doi: 10.1016/j.amjcard.2011.05.020. Epub 2011 Aug 2.

PMID:
21816379
18.

Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes.

Armero S, Bonello L, Berbis J, Camoin-Jau L, Lemesle G, Jacquin L, Bonello-Burignat C, Pansieri M, Collet F, Ostorero M, Dignat-George F, Paganelli F.

Am J Cardiol. 2011 Dec 15;108(12):1710-3. doi: 10.1016/j.amjcard.2011.07.038. Epub 2011 Sep 8.

PMID:
21906705
19.

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.

Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P; ACCOAST Investigators..

N Engl J Med. 2013 Sep 12;369(11):999-1010. doi: 10.1056/NEJMoa1308075. Epub 2013 Sep 1.

20.

Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study.

Alexopoulos D, Moulias A, Koutsogiannis N, Xanthopoulou I, Kakkavas A, Mavronasiou E, Davlouros P, Hahalis G.

Circ Cardiovasc Interv. 2013 Jun;6(3):277-83. doi: 10.1161/CIRCINTERVENTIONS.113.000293. Epub 2013 Jun 4.

Supplemental Content

Support Center